Wednesday - July 16, 2025
EAGLE, Idaho, April 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of the real estate and operations of an established senior living community in Arizona. The newly acquired community offers assisted living and memory care services, and increases Pennant’s Arizona operations by 128 units.
“This acquisition aligns with our mission to provide life-changing service as we create active, supportive communities where seniors can thrive,” said Brent Guerisoli, Chief Executive Officer of Pennant. “By expanding our services and adding to the strong portfolio of existing properties in Arizona, Pennant is reinforcing its commitment to providing high-quality, compassionate care for our residents.”
The Arizona acquisition marks Pennant’s fourth senior living community acquisition in 2025 and first real estate purchase for the year. “We are excited about the opportunity to revitalize this Arizona senior living community and provide quality care and support to its residents,” added Andrew Rider, President of Pinnacle Senior Living LLC, Pennant’s senior living subsidiary. “Our focus is on stability, excellence, and strengthening the living experience for seniors in Arizona.”
Pennant looks forward to working closing with residents, families, and staff to ensure a smooth transition and a bright future for this community.
About Pennant:
The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through home health and hospice agencies and senior living communities located throughout Arizona, California, Colorado, Connecticut, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.
Last Trade: | US$24.46 |
Daily Change: | -0.89 -3.51 |
Daily Volume: | 216,340 |
Market Cap: | US$843.140M |
May 16, 2025 May 06, 2025 February 27, 2025 February 03, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load